Browse MECOM

Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Nucleus speckle.
Domain -
Function

Isoform 1: Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. May also play a role in apoptosis through regulation of the JNK and TGF-beta signaling. Involved in hematopoiesis.

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0006479 protein methylation
GO:0007254 JNK cascade
GO:0008213 protein alkylation
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018205 peptidyl-lysine modification
GO:0031098 stress-activated protein kinase signaling cascade
GO:0032259 methylation
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032873 negative regulation of stress-activated MAPK cascade
GO:0034968 histone lysine methylation
GO:0042326 negative regulation of phosphorylation
GO:0043409 negative regulation of MAPK cascade
GO:0043414 macromolecule methylation
GO:0046328 regulation of JNK cascade
GO:0046329 negative regulation of JNK cascade
GO:0051403 stress-activated MAPK cascade
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070303 negative regulation of stress-activated protein kinase signaling cascade
GO:0071425 hematopoietic stem cell proliferation
GO:0072089 stem cell proliferation
GO:1902532 negative regulation of intracellular signal transduction
Molecular Function GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016278 lysine N-methyltransferase activity
GO:0016279 protein-lysine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0018024 histone-lysine N-methyltransferase activity
GO:0042054 histone methyltransferase activity
Cellular Component GO:0000118 histone deacetylase complex
GO:0016234 inclusion body
GO:0016235 aggresome
GO:0016604 nuclear body
GO:0016607 nuclear speck
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3214841: PKMTs methylate histone lysines
Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MECOM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MECOM in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MECOM in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8630.015
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9710.18
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7860.195
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2540.594
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6250.809
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1980.945
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5710.245
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6770.499
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4370.696
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2740.787
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3990.277
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2860.166
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MECOM in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277325.912.313.60.126
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275925.915.310.60.248
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.823.50.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.836.4-5.61
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382721.17.413.70.175
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221327.3027.30.0645
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.514.3-1.81
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.17.71.41
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MECOM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MECOM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MECOM.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MECOM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MECOM expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MECOM and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMECOM
NameMDS1 and EVI1 complex locus
Aliases MDS1-EVI1; PRDM3; MDS1; EVI1; myelodysplasia syndrome 1; ecotropic viral integration site 1; MDS1 and EVI1 c ......
Chromosomal Location3q26.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MECOM collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.